Peyrin-Biroulet L - Search Results

1

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.

Ruiz-Casas L, Evans J, Rose A, Pedra GG, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, Burisch J, Terry H, Avedano L, Tucknott S, Fiorino G, Limdi J. Ruiz-Casas L, et al. BMC Gastroenterol. 2021 Dec 4;21(1):456. doi: 10.1186/s12876-021-02028-5. BMC Gastroenterol. 2021. PMID: 34863112 Free PMC article.

2

A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.

Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourié B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Am J Gastroenterol. 2010 Dec;105(12):2617-25. doi: 10.1038/ajg.2010.345. Epub 2010 Aug 24. Am J Gastroenterol. 2010. PMID: 20736936

3

Adalimumab in ulcerative colitis: hypes and hopes.

Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, Danese S. Fiorino G, et al. Expert Opin Biol Ther. 2011 Jan;11(1):109-16. doi: 10.1517/14712598.2011.541435. Expert Opin Biol Ther. 2011. PMID: 21133817 Review.

4

Update on Crohn's disease and ulcerative colitis.

Billioud V, Allen PB, Peyrin-Biroulet L. Billioud V, et al. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):311-4. doi: 10.1586/egh.11.35. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21651348

5

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.

Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Fiorino G, et al. Inflamm Bowel Dis. 2012 Jun;18(6):1042-7. doi: 10.1002/ibd.21800. Epub 2011 Jun 14. Inflamm Bowel Dis. 2012. PMID: 21674732 Clinical Trial.

6

Capsule endoscopy in Crohn's disease.

Chevaux JB, Fiorino G, Frederic M, Peyrin-Biroulet L. Chevaux JB, et al. Curr Drug Targets. 2012 Sep 1;13(10):1261-7. doi: 10.2174/138945012802429732. Curr Drug Targets. 2012. PMID: 22664083

7

Bowel damage assessment in Crohn's disease by magnetic resonance imaging.

Fiorino G, Peyrin-Biroulet L, Danese S. Fiorino G, et al. Curr Drug Targets. 2012 Sep 1;13(10):1300-7. doi: 10.2174/138945012802429705. Curr Drug Targets. 2012. PMID: 22702635 Review.

8

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. Peyrin-Biroulet L, et al. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):345-51. doi: 10.1038/nrgastro.2013.31. Epub 2013 Mar 5. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23458890 Review.

9

Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease.

Fiorino G, Bonifacio C, Padrenostro M, Sposta FM, Spinelli A, Malesci A, Balzarini L, Peyrin-Biroulet L, Danese S. Fiorino G, et al. Dig Dis Sci. 2013 Nov;58(11):3246-55. doi: 10.1007/s10620-013-2781-z. Epub 2013 Aug 1. Dig Dis Sci. 2013. PMID: 23903867

10

Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Danese S, et al. Ann Intern Med. 2014 May 20;160(10):704-11. doi: 10.7326/M13-2403. Ann Intern Med. 2014. PMID: 24842416 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,106 results

Search Page

Filters